Research programme: chimeric immunomodulatory DNA - Dynavax

Drug Profile

Research programme: chimeric immunomodulatory DNA - Dynavax

Alternative Names: Chimeric immunomodulatory compounds - Dynavax; Chimeric immunomodulatory oligonucleotides - Dynavax; CIC - Dynavax

Latest Information Update: 16 Apr 2008

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Class Oligonucleotides
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Viral infections

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 16 Apr 2008 Discontinued - Preclinical for Viral infections in USA (unspecified route)
  • 25 Sep 2006 Chimeric immunomodulatory DNA compounds are still in preclinical trials in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top